Definiens | GenomeWeb

Definiens

Takeda will use Definiens' new cloud-based digital pathology platform to conduct analyses for its clinical biomarkers development programs.

The companies will offer customers access to their technologies and services for cancer image analysis and tissue-based biomarker research and development.

The companies will combine MolecularMD's specialty diagnostic assays with Definiens' quantitative tissue read-outs to provide customized diagnostic solutions in oncology.

While the deal has provided AstraZeneca and MedImmune access to the tissue phenomics technology, Definiens now has broader and clearer access to patients.

 

NEW YORK (GenomeWeb) – AstraZeneca today announced its biologics research and development arm MedImmune has reached a deal to purchase digital pathology products firm Definiens.

NEW YORK (GenomeWeb) – Definiens announced today that it has raised €15 million ($20.4 million) in a private round of financing that will support the firm's efforts to expand its business into digital tissue diagnostics.

NEW YORK (GenomeWeb News) – Definiens and Metamark Genetics today announced a multiyear agreement for use of Definiens' image analysis product for Metamark's prostate cancer prognostic test.

Vermillion said this week that at its annual meeting on March 21, shareholders elected Robert Goggin to the company's board of directors.

Quantitative digital pathology firm Definiens has appointed a new advisory board to provide independent advice on trends in tissue diagnostics and clinical digital pathology.

Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Ronald DePinho, an oncologist at the University of Texas MD Anderson Cancer Center.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.